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In the second cohort of patients with early disease no patient
showed any signs of clinical or radiographic ankylosis of the
small joints in the hand.
To conclude, the present data suggest that the prevalence of
small joint ankylosis in RA is low and confined to patients with
longstanding severe disease. This may be an indication of the
possibility that ankylosis in RA is a vanishing phenomenon,
possibly owing to more efficient treatment options. However,
this pilot study shows that it is still feasible to identify in
clinical practice small joint ankylosis in patients with RA. The
possibility that this manifestation of RA may be a clue to
important pathogenetic mechanisms in RA and the spondylo-
arthropathies argues in favour of identifying these patients and
including them in pathogenetic studies of these diseases.
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Intra-articular infliximab in patients
with rheumatoid arthritis and
psoriatic arthritis with monoarthritis
resistant to local glucocorticoids.
Clinical efficacy extended to
patients on systemic anti-tumour
necrosis factor a
Some experiences with intra-articular (IA) infliximab treatment
in patients with refractory monoarthritis have been reported,
even though these studies have important limitations including
small sample size and short trial duration.1–4
Aim of this study was to evaluate the efficacy and safety of
IA infliximab administration in a larger cohort of patients. We
studied 10 patients with rheumatoid arthritis (RA) and seven
with psoriatic arthritis (PsA) with active monoarthritis lasting
at least 3 months, refractory to disease-modifying antirheu-
matic drugs (DMARDs) and to IA glucocorticoids.5 6 DMARDs
dose had to be stable for at least 6 weeks before IA injection of
infliximab, and it was maintained stable throughout the follow-
up. IA methylprednisolone had to have been injected at least
6 weeks before the procedure. Concomitant treatment with
anti-TNFa other than infliximab was permitted; indeed the
biologic agent was stopped 2 weeks before and restarted
2 weeks after IA procedure. After removing synovial fluid, IA
infliximab was injected at dosage of 100 mg for the knee, 50 mg
for the ankle, 25 mg for the wrist.
Patients were evaluated at baseline, and after 2 and 12 weeks
for visual analogue scale (VAS) for pain, and the degree of
swelling and tenderness (0–3).2 3 The sum of swelling and
tenderness scores provided the total arthritis score (0–6).
Erythrocyte sedimentation rate (ESR, mm/h) and C-reactive
protein (CRP, mg/dl) were also evaluated. Ultrasonographic
examination of the inflamed joint was performed by the same
rheumatologist, an arbitrary scoring system (0–6) for assess-
ment of inflamed joint was applied considering synovial
hypertrophy (0–3) and power Doppler evaluation (0–3).7–9
Table 1 and fig 1 show the clinical features and the outcome
parameters of the enrolled patients.
Two and 12 weeks after treatment a clinical response was
seen in nine of 10 (90%) RA patients. Regarding patients with
PsA, after 2 weeks a clinical response was seen in six of
seven (85.7%) patients, and after 12 weeks in four of seven
(57.1%) patients. No local or systemic adverse reactions were
Table 1 Clinical and radiological features/data of six patients with rheumatoid arthritis (RA) and spontaneous small joint ankyloses in the hands
Patient Sex
Age*
(years)
Disease
duration
(years)
Small joint
ankylosis RF Nodules HLA-B27
x-Ray
examination1
Normal SI
joints?
Psoriasis or
in family
RA criteria
items
fulfilled
Ankylosing
spondylitis"
1 F 68* 26 PIP II, III left hand + Yes Not done Yes Yes No 7/7 No
2 F 78 26 PIP II both hands + No No{ Yes Yes 6/7 No
3 M 79* 19 PIP IV, V left hand + Yes No Yes Yes No 7/7 No
4 F 79 32 PIP II, III right hand + No Not done Yes Yes No 6/7 No
5 F 82 40 PIP II both hands
and III left hand
– No No Yes Yes Yes 5/7 No
6 F 83 49 PIP III, V right hand,
os carpale right
wrist
+ No Yes{ Yes Yes No 6/7 No
*Age at death; {HLA type classes I A02 A33 B14 B40, class II DR 04 DR 15; {HLA type classes I A02 A03 B15 B27, class II DR 04 DR 15; 1symmetrical, severe, erosive changes in large
and small joints; "the 1966 New York criteria fulfilled.
PIP, proximal interphalangeal; RF, rheumatoid factor; SI, sacroiliac.
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documented. In patients with RA and PsA the US score
correlated positively with the total arthritis score at 12 weeks
(p,0.05).
The results of this study suggest that patients with RA and
PsA with refractory monoarthritis could be successfully treated
with IA infliximab. The ultrasonographic features of synovitis
significantly improved during the follow-up and correlated
positively with the outcome measures, confirming the biologic
effect of IA infliximab. In patients with a secondary failure of
treatment, a second IA injection of infliximab determined a
complete response in all the cases.
IA infliximab resulted efficacious in five of six patients who
were receiving systemic TNFa antagonists other than inflix-
imab. Changing anti-TNFa and inoculating it directly in the site
Figure 1 Clinical parameters in patients
affected by rheumatoid arthritis (n = 10,
column 1) and psoriatic arthritis (n = 7,
column 2) with refractory monoarthritis
treated with intra-articular administration
of infliximab. Box and whiskers plot
(median, quartiles, range and possible
extreme values) of: (A) visual analogue
scale for pain; (B) degree of swelling; (C)
degree of tenderness; (D) erythrocyte
sedimentation rate; (E) C-reactive protein;
(F) ultrasonographic score. Values shown
are the mean values at baseline (before
intra-articular infliximab treatment), 2 and
after 12 weeks after treatment. The
Wilcoxon paired test was used to
compare quantitative variables in the
same group. *p,0.01 vs baseline,
pˆ,0.05 vs baseline, 1p,0.05 vs
2 weeks.
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of inflammation determined a good clinical response. Use of IA
infliximab in this cohort of patients with RA and PsA with
resistant monoarthritis provides evidence that it could be an
efficacious and safe therapeutic option determining a sustained
clinical improvement also in patients on other anti-TNFa.
Considering the sample size of this study, larger prospective
trials are needed in order to confirm these preliminary findings.
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Increased blood glucose levels
following intra-articular injection of
methylprednisolone acetate in
patients with controlled diabetes
and symptomatic osteoarthritis of
the knee
The effect of oral or intravenous steroid treatment on glucose
metabolism is well known.1 Intra-articular steroid injection
(IASI) at the knee joint is a common procedure,2 however there
are no studies on the effect of IASI on glucose metabolism.
Patients with controlled diabetes (HgA1C,7), using modern
versions of blood glucose monitoring devices, with knee pain
due to osteoarthritis of the knee (OAK) for more than 3 months
without sufficient response to non-steroidal anti-inflammatory
drugs (NSAIDs) and physical therapy were offered an IASI of
50 mg of methylprednisolone acetate (MPA) (Pharmacia &
Upjohn, Puurs, Belgium) at the knee joint. If they agreed,
patients were asked to monitor their blood glucose levels before
and 2 h after breakfast, lunch and supper every other day for 1
week prior to injection and daily for 4 days, then every other
day for 10 days following the injection using the same glucose
monitoring devices. All the IASIs were performed in the
morning following breakfast, after maximal aspiration of knee
fluid (if any). Patients were asked to continue the same regimen
of physical activity, diet and antidiabetic treatment. For
statistical analysis, a significant increase in blood glucose level
after the injection were considered if the levels were higher by at
least 2 SD in relation to the mean comparable glucose level (in
reference to meals) before the injection. The study was
approved by the Helsinki committee of the Nazareth
Hospital, and all the patients signed a consent form.
Nine patients with type 2 diabetes were injected and all
completed the study. Seven patients were female and four
patients were treated with diet only. Significant increase in
blood glucose levels following the IASI were documented in all
the patients however prominent increase was seen in seven
patients, and in two patients the increase was minimal with a
flat curve. A significant increase was seen as early as 2–4 h after
the injection in four patients and 12–26 h in the rest of the
patients (table 1). Peak levels were seen after nearly 5 h in three
Table 1 Time relation of glucose levels following intra-articular steroid injection (IASI)
Patient no.
Time to earliest
significantly
increased glucose
level, h
Earliest
significantly
increased glucose
level, mg %
Time to peak
glucose levels, h
Peak glucose
levels, mg %
Time to return to
baseline levels, h
1 4 339 5 375 68
2 4 160 5 310 52
3 2 184 17 283 42
4 12 227 32 463 48
5 2 134 5 314 70
6 26 249 84 282 96
7 12 255 48 500 104
8 20 154 24 191 48
9 14 150 48 165 58
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